MedTrace Logo

Pulmonary Capillary Recruitment in Fontan Patients

NCT04292483 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2022-04-07

No results posted yet for this study

Summary

This study evaluates the effects of pulmonary vasodilator therapy on pulmonary capillary blood flow by measuring the functional capillary surface area (FCSA) at baseline and post nitric oxide inhalation, through the injection of 3H-benzoyl-Phe-Ala-Pro (BPAP). FCSA will be related to flow and other hemodynamic parameters in order to determine if there is capillary recruitment or distention in Fontan patients. We will also compare baseline FCSA measurements with previously studied normal subjects, to assess the difference in hemodynamic pulmonary functional parameters between these single ventricle physiology patients and normal subjects.

Conditions

  • Congenital Heart Disease

Interventions

DRUG

Nitric Oxide

Inhaled vasodilator to increase pulmonary capillary perfusion

Sponsors & Collaborators

  • National and Kapodistrian University of Athens

    collaborator OTHER

  • Tel Aviv University

    collaborator OTHER

  • Old Dominion University

    collaborator OTHER

  • Jewish General Hospital

    lead OTHER

Principal Investigators

  • David Langleben, MD · Jewish General Hospital

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-11
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04292483 on ClinicalTrials.gov